Abstract
Introduction Diffusion-weighted imaging (DWI) on MRI-linear accelerator (MR-linac) systems can potentially be used for monitoring treatment response and adaptive radiotherapy in head and neck cancers (HNC) but requires extensive validation. We perform technical validation to compare six total DWI sequences on an MR-linac and MR simulator (MR sim) in patients, volunteers, and phantoms.
Methods Ten human papillomavirus-positive oropharyngeal cancer patients and ten volunteers underwent DWI on a 1.5T MR-linac with three DWI sequences: echo planar imaging (EPI), split acquisition of fast spin echo signals (SPLICE), and turbo spin echo (TSE). Volunteers were also imaged on a 1.5T MR sim with three sequences: EPI, BLADE, and RESOLVE. Participants underwent two scan sessions per device and two repeats of each sequence per session. Repeatability and reproducibility within-subject coefficient of variation (wCV) of mean ADC were calculated for tumors and lymph nodes (patients) and parotid glands (volunteers). Differences in measured ADC values between sequences were quantified using Bland-Altman analysis. ADC bias, repeatability/reproducibility metrics, and SNR were quantified using a phantom.
Results In vivo repeatability/reproducibility wCV of mean ADC for parotids were 5.41%/6.72%, 3.83%/8.80%, 5.66%/10.03%, 3.44%/5.70%, 5.04%/5.66%, 4.23%/7.36% for EPIMR-linac, SPLICE, TSE, EPIMR sim, BLADE, RESOLVE. Repeatability/reproducibility wCV for EPIMR-linac, SPLICE, TSE were 9.64%/10.28%, 7.84%/8.96%, 7.60%/11.68% for tumors and 7.80%/9.95%, 7.23%/8.48%, 10.82%/10.44% for nodes. Bland-Altman analysis revealed significant differences between all sequence pairs except BLADE-EPIMR-linac and RESOLVE-SPLICE. All sequences except TSE had phantom ADC biases within ±0.1×10−3 mm2/s for most vials. MR-linac sequences had inconsistent ADC values between different vials with the same known ADC value, indicating spatial inhomogeneities. SNR of b=0 images was 87.3, 180.5, 161.3, 171.0, 171.9, 130.2 for EPIMR-linac, SPLICE, TSE, EPIMR sim, BLADE, RESOLVE.
Conclusion MR-linac DWI sequences demonstrate near-comparable performance to MR sim sequences and warrant further clinical validation for treatment response assessment in HNC.
Competing Interest Statement
J. Christodouleas and A. Dresner are employees of Elekta AB and Philips, respectively, and have collaborated on this project as part of an academic-industrial partnership R01 grant (R01DE028290). C. D. Fuller has received industry research support from Elekta AB. C. D. Fuller and B. A. McDonald have received travel funding and speaking honoraria from Elekta AB unrelated to the current project.
Funding Statement
C.D. Fuller and J. Christodouleas receive research support from an academic-industrial partnership R01 grant from the National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research (NIDCR) (R01DE028290) directly related to this project. B.A. McDonald is funded by a Ruth L. Kirschstein fellowship from NIH/NIDCR (1F31DE029093) and a Dr. John J. Kopchick Fellowship from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. C.D. Fuller has received industry research support from Elekta AB. C.D. Fuller reports additional grants from NIH/National Cancer Institute (R01CA218148, 1R01CA225190, 1R01CA214825, P30CA016672, P50CA097007-10), NIH/NIDCR (1R01DE025248/R56DE025248), NIH/National Institute of Biomedical Imaging and Bioengineering (R25EB025787), Patient-centered Outcomes Research Institute (PCS-1609-36195), Sister Institute Network Fund (MD Anderson), and National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation (CMMI 1933369), outside of the scope of the current project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent. Patients were consented to the MOMENTUM observational clinical trial (NCT04075305) and volunteers to an internal volunteer imaging protocol (PA15-0418), both approved by the institutional review board at MD Anderson Cancer Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The images and segmentations used for this project will be anonymized and made available in a public data repository by the time of publication.
